No Data
No Data
12 Health Care Stocks Moving In Friday's Pre-Market Session
NASDAQ New 52-Week Highs And Lows
Actuate Therapeutics Gets Orphan Medicinal Product Label for Elraglusib in EU
Express News | Actuate Therapeutics Inc: To Report Topline Data From Phase 2 Trial of Elraglusib in 1H 2025
Express News | Actuate Therapeutics Inc - Statistical Significance Met on Primary Endpoints in Phase 2 Trial
Express News | Actuate Therapeutics Inc - Elraglusib in Combination With Gnp Shows Favorable Risk-Benefit Profile